Vincristine News and Research

RSS

Vincristine is the active ingredient in a drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Vincristine is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.

Medical College of Wisconsin receives grant to study infantile hemangiomas

The Food and Drug Administration (FDA) has awarded the Medical College of Wisconsin in Milwaukee a three-year, $1 million Orphan Products Development grant to study infantile hemangiomas – a vascular tumor of the skin or internal organs.

25 Oct 2007

New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas

Childhood brainstem gliomas (BSGs) are rare but can be very difficult to treat successfully and they tend to have poor survival rates.

26 Sep 2007

New hope for common form of childhood cancer

Dr. Richard Lock, Head of the Leukaemia Biology Program at the Children's Cancer Institute Australia for Medical Research, Sydney, along with collaborators from the Childrens Hospital Los Angeles and University of Southern California, USA, recently published their findings in the prestigious scientific journal Blood.

23 Jul 2007

New hope for childhood cancer sufferers

Scientists investigating drug therapies for children with Acute Lymphoblastic Leukaemia (ALL) have presented new data demonstrating for the very first time that a small molecule called ABT-737 can increase the effectiveness of standard therapies.

17 Jul 2007

Novel cellular mechanism that may guide cell movement and possibly cancer cell invasion

Scientists have long thought that microtubules, part of the microscopic scaffolding that the cell uses to move things around in order to hold its shape and divide, originated from a tiny structure near the nucleus, called the centrosome.

23 Jun 2007

Adding radioimmunotherapy to chemo may help patients with lymphoma

Patients treated for follicular lymphoma, a slow-growing type of non-Hodgkin's lymphoma, may benefit from chemotherapy followed by radioimmunotherapy, according to a University of Pittsburgh Medical Center (UPMC) study presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago and published as Abstract 8005 in the ASCO proceedings.

5 Jun 2007

New chemical agent, MCP110, provides synergistic effect to standard drugs

Integrating the use of drugs targeted to specific cancer proteins into current chemotherapy regimens to improve the efficacy of systemic treatment is an important clinical goal at Fox Chase Cancer Center.

16 Apr 2007

New radiotherapy/chemotherapy strategy improves outcomes for children with medulloblastoma

Radiotherapy that is adapted for the severity of disease and followed by a shortened course of chemotherapy substantially improves the outcome of children with a type of brain tumour called medulloblastoma, claim investigators in an Online/Article in The Lancet Oncology.

7 Sep 2006

Combination therapy improves Acquired Immunodeficiency Syndrome-Related Lymphoma outcome

Combining aggressive HIV therapy and chemotherapy significantly improves the survival rates of HIV-positive men and women treated for lymphoma, according to a new study.

27 Feb 2006

New treatment advances for patients with follicular lymphoma

A newly published study recommends that doctors carefully choose their patients' initial therapies because there are significant differences in overall survival rates, according to researchers at the University of Rochester Medical Center's James P. Wilmot Cancer Center.

20 Oct 2005

New treatment for the pediatric eye cancer retinoblastoma

Investigators at St. Jude Children's Research Hospital have demonstrated in laboratory studies a new treatment for the pediatric eye cancer retinoblastoma that appears to be more effective than the current standard therapy, and more likely to prevent the recurrence of this cancer. A report on their work appears in the October 15 issue of Clinical Cancer Research.

17 Oct 2005

Rev/Dex combo looks like a breakthrough treatment for multiple myeloma

Mayo Clinic Cancer Center investigators report that combination therapy with lenalidomide (Revlimid) and dexamethasone (combination is called Rev/Dex) looks like a breakthrough treatment for multiple myeloma. Results of a Phase II clinical trial were published online Aug. 23 in Blood.

1 Sep 2005

Medulloblastoma irradiation may impair reading skills in young children

Irradiation therapy for the brain cancer medulloblastoma is more likely to impair IQ and reading skills of younger children than older children even if the dose of radiation is reduced, according to the results of the largest study of its kind, conducted by investigators at St. Jude Children's Research Hospital, Texas Children's Cancer Center (Houston) and Royal Children's Hospital (Melbourne, Australia).

22 Aug 2005

Urine testing may predict birthmarks

Vascular anomalies - birthmarks caused by abnormal development of arteries, capillaries, veins or lymph vessels - can sometimes begin to progress, requiring aggressive treatment to save the child's health or vision. Research at Children's Hospital Boston now suggests that urine testing can help monitor these anomalies and predict those about to become a serious threat.

6 Jul 2005

Thalidomide may be a potent anti-cancer treatment

When people hear "thalidomide," many think "birth defects," however, evidence has come to light that this once-banned drug can be used as a potent anti-cancer treatment.

20 Jun 2005

Pattern of gene expression predicts multiple drug resistance, treatment failure in pediatric leukemia

The discovery of a specific pattern of gene expression linked to multiple-drug resistance of leukemic cells is giving researchers crucial information into why standard therapies fail to cure some children with acute lymphoblastic leukemia (ALL). This finding, from investigators at St. Jude Children’s Research Hospital, could lead to development of drugs that would overcome that resistance.

24 Apr 2005

Gene expression pattern predicts multiple drug resistance

St. Jude Children's Research Hospital discovery of genetic links to multi-drug resistance gives clinicians new insight into the cause of treatment failure and suggests targets for novel anti-leukemic drugs

19 Apr 2005

Researchers turn fatal brain cancer into treatable disease for children

Some children with a rare brain tumor that is considered almost universally fatal can be saved if they receive radiation therapy followed by tandem (given one after the other) cycles of high-dose chemotherapy.

3 Mar 2005

FDA knocks back anticancer drug Marqibo

Inex Pharmaceuticals announced today that United States Food and Drug Administration (FDA) provided an action letter detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval regulations based on the phase 2 clinical trial data submitted.

19 Jan 2005

Combination of thalidomide and dexamethasone may be a promising treatment for multiple myeloma

The combination of two pills -- thalidomide and dexamethasone -- may be an effective alternative to the intravenous chemotherapy commonly prescribed to patients with multiple myeloma, according to a large collaborative study conducted by the Eastern Cooperative Oncology Group and led by a Mayo Clinic investigator.

7 Dec 2004